Corporate ActionJun 24, 2026, 04:03 PM
Taysha Gene Therapies Announces $200M Public Offering
AI Summary
Taysha Gene Therapies, a clinical-stage biotechnology company, announced the commencement of an underwritten public offering to raise $200.0 million. The offering includes common stock and pre-funded warrants, with an option for underwriters to purchase an additional 15% of shares. The offering is subject to market conditions and will be made via a prospectus supplement and accompanying prospectus.
Key Highlights
- Taysha Gene Therapies commenced an underwritten public offering of $200.0 million.
- The offering includes shares of common stock and pre-funded warrants.
- Underwriters have a 30-day option to purchase up to an additional 15% of shares.
- Jefferies, Goldman Sachs, Piper Sandler, and Cantor are joint book-running managers.
- Baird is acting as the lead manager for the proposed offering.
Price Impact
More from TSHA